RESUMO
OBJECTIVE: To examine potential genetic relationships between migraine and the two distinct phenotypes posterior circulation ischemic stroke (PCiS) and anterior circulation ischemic stroke (ACiS), we generated migraine polygenic risk scores (PRSs) and compared these between PCiS and ACiS, and separately vs. non-stroke control subjects. METHODS: Acute ischemic stroke cases were classified as PCiS or ACiS based on lesion location on diffusion-weighted MRI. Exclusion criteria were lesions in both vascular territories or uncertain territory; supratentorial PCiS with ipsilateral fetal posterior cerebral artery; and cases with atrial fibrillation. We generated migraine PRS for three migraine phenotypes (any migraine; migraine without aura; migraine with aura) using publicly available GWAS data and compared mean PRSs separately for PCiS and ACiS vs. non-stroke control subjects, and between each stroke phenotype. RESULTS: Our primary analyses included 464 PCiS and 1079 ACiS patients with genetic European ancestry. Compared to non-stroke control subjects (n=15396), PRSs of any migraine were associated with increased risk of PCiS (p=0.01-0.03) and decreased risk of ACiS (p=0.010-0.039). Migraine without aura PRSs were significantly associated with PCiS (p=0.008-0.028), but not with ACiS. When comparing PCiS vs. ACiS directly, migraine PRSs were higher in PCiS vs. ACiS for any migraine (p=0.001-0.010) and migraine without aura (p=0.032-0.048). Migraine with aura PRS did not show a differential association in our analyses. CONCLUSIONS: Our results suggest a stronger genetic overlap between unspecified migraine and migraine without aura with PCiS compared to ACiS. Possible shared mechanisms include dysregulation of cerebral vessel endothelial function.
Assuntos
AVC Isquêmico , Enxaqueca com Aura , Enxaqueca sem Aura , Imagem de Difusão por Ressonância Magnética , Humanos , Enxaqueca com Aura/diagnóstico por imagem , Enxaqueca com Aura/genética , Enxaqueca sem Aura/diagnóstico por imagem , Enxaqueca sem Aura/genética , Fatores de RiscoRESUMO
Several different mechanisms of magnetoresistance (MR) have been observed in 1111 LnMnAsO1-xFx oxypnictides (Ln = lanthanide) as a result of magnetic coupling between the Mn and Ln. Such phases also exhibit interesting magnetic phase transitions upon cooling. Sr2Mn2CrAs2O2 has been synthesized to investigate if it is possible to observe MR and/or magnetic phase transitions as a result of magnetic coupling between the Mn and Cr. Sr2Mn2CrAs2O2 crystallizes in the tetragonal space group I4/mmm containing alternating MO22- and M'2As22- layers, and neutron diffraction results demonstrate that the actual stoichiometry is Sr2Mn2.23Cr0.77As2O2. Cation order is present between Mn and Cr, with Cr predominantly occupying the square planar MO22- site. Below 410 K, the magnetic moments of the Mn/Cr ions in the M'2As22- sublattice exhibit G-type antiferromagnetic order. The Mn/Cr moments within the MO22- layer order below 167 K with a K2NiF4-type antiferromagnetic structure that simultaneously induces a spin flip of the magnetic moments in the M'2As22- layers from a G-type to a C-type antiferromagnetic arrangement. The results demonstrate that the superexchange interactions are finely balanced in Sr2Mn2.23Cr0.77As2O2. Sr2Mn2.23Cr0.77As2O2 is semiconducting, and there is no evidence of MR.
RESUMO
OBJECTIVE: Investigate a role for calcitonin gene-related peptide (CGRP) in osteoarthritis (OA)-related pain. DESIGN: Neutralizing antibodies to CGRP were generated de novo. One of these antibodies, LY2951742, was characterized in vitro and tested in pre-clinical in vivo models of OA pain. RESULTS: LY2951742 exhibited high affinity to both human and rat CGRP (KD of 31 and 246 pM, respectively). The antibody neutralized CGRP-mediated induction of cAMP in SK-N-MC cells in vitro and capsaicin-induced dermal blood flow in the rat. Neutralization of CGRP significantly reduced pain behavior as measured by weight bearing differential in the rat monoiodoacetate model of OA pain in a dose-dependent manner. Moreover, pain reduction with neutralization of CGRP occurred independently of prostaglandins, since LY2951742 and NSAIDs worked additively in the NSAID-responsive version of the model and CGRP neutralization remained effective in the NSAID non-responsive version of the model. Neutralization of CGRP also provided dose-dependent and prolonged (>60 days) pain reduction in the rat meniscal tear model of OA after only a single injection of LY2951742. CONCLUSIONS: LY2951742 is a high affinity, neutralizing antibody to CGRP. Neutralization of CGRP is efficacious in several OA pain models and works independently of NSAID mechanisms of action. LY2951742 holds promise for the treatment of pain in OA patients.
Assuntos
Anticorpos Neutralizantes/farmacologia , Peptídeo Relacionado com Gene de Calcitonina/efeitos dos fármacos , Osteoartrite/tratamento farmacológico , Dor/prevenção & controle , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Peptídeos Catiônicos Antimicrobianos , Catelicidinas/metabolismo , Modelos Animais de Doenças , Humanos , Masculino , Ratos , Ratos Endogâmicos Lew , Fluxo Sanguíneo Regional , Pele/irrigação sanguíneaRESUMO
OBJECTIVES: During mass antibiotic distributions for trachoma, certain individuals are difficult to locate and go untreated. These untreated individuals may serve as a source of community reinfection. The importance of this difficult-to-locate, untreated population is unclear. We sought to determine whether individuals who are difficult to locate were more likely to be infected with ocular chlamydia than those who were easier to locate. METHODS: We monitored 12 Ethiopian communities 1 year after a third annual mass azithromycin treatment for trachoma. Conjunctival swabbing for chlamydial RNA was performed in a random sample of children from each community. If insufficient numbers of children were enrolled on the first monitoring day, we returned on subsequent days. RESULTS: Of the 12 communities, 10 required more than one monitoring day. On average, 16.1% (95% CI 7.9-30.0) of children were enrolled after the initial day. Evidence of chlamydia was found in 7.1% (95% CI 2.7-17.4) of 0- to 9-year-old children. No ocular swabs collected after the initial day were positive for chlamydial RNA. Children examined after the initial monitoring day were significantly less likely to have ocular chlamydial infection than children seen on the initial day; Mantel-Haenszel common OR = 0 (95% CI 0-0.77). CONCLUSIONS: In a setting of repeated annual mass azithromycin treatments, after approximately 80% of individuals have been located in a community, extra efforts to find absent individuals may not yield significantly more cases of ocular chlamydia.
Assuntos
Azitromicina/uso terapêutico , Chlamydia trachomatis/genética , Túnica Conjuntiva/microbiologia , Atenção à Saúde , Acessibilidade aos Serviços de Saúde , Vigilância da População , Tracoma/diagnóstico , Humanos , Razão de Chances , Características de Residência , Tracoma/tratamento farmacológico , Tracoma/epidemiologia , Tracoma/microbiologiaRESUMO
The 8.12 idiotype characterizes a subpopulation of anti-DNA antibodies in patients with systemic lupus erythematosus (SLE). The idiotype is present on lambda light chains and has previously been shown to be exclusively encoded by V lambda II light chains. RFLP analysis of the V lambda II gene family has shown the family to consist of 10 to 15 members. Thus far, the sequences of seven V lambda II germline genes are reported in the literature with one of these a pseudogene. To identify the V lambda II genes that encode 8.12 positive antibodies and to further characterize the V lambda II family, germline V lambda II clones were derived from a patient with SLE. Two libraries were constructed: a genomic DNA library and a library of PCR-derived V lambda II gene products obtained using a conserved V lambda II leader region primer and a primer for the nonamer region 3' of the coding sequence. We now describe seven new germline genes, two of which are pseudogenes. Comparison of V lambda II germline genes to sequences of 8.12 positive light chains produced by EBV-transformed B cell lines show that all 8.12 positive light chains are encoded by a limited number of highly homologous members of the V lambda II family. 8.12 negative V lambda II encoded light chains also derive from a limited number of V lambda II genes, suggesting that only a subset of the apparently available V lambda II genes are commonly expressed.
Assuntos
Genes de Imunoglobulinas , Região Variável de Imunoglobulina/genética , Cadeias lambda de Imunoglobulina/genética , Lúpus Eritematoso Sistêmico/genética , Sequência de Aminoácidos , Sequência de Bases , Biblioteca Gênica , Humanos , Dados de Sequência Molecular , Reação em Cadeia da PolimeraseRESUMO
AIM: To compare the prevalence of antibiotic resistance found in nasopharyngeal Streptococcus pneumoniae between villages treated with topical tetracycline or systemic azithromycin as part of a trachoma control programme. METHODS: All children aged 1-10 years were offered either single dose oral azithromycin treatment (20 mg/kg) or a course of topical 1% tetracycline ointment, depending on the area. Treatment was given annually for 3 years. Six months after the third annual treatment in each village, children were surveyed for nasopharyngeal carriage of S pneumoniae and resistance was determined using broth dilution MIC technique. Children in two additional villages, which had not yet been treated, were also surveyed. RESULTS: Nasopharyngeal carriage of S pneumoniae was similar in the tetracycline treated, azithromycin treated, and untreated areas (p=0.57). However, resistance to tetracycline and azithromycin was distributed differently between the three areas (p=0.004). The village treated with topical tetracycline had a higher prevalence of tetracycline resistance than the other villages (p=0.010), while the oral azithromycin treated village had a higher prevalence of macrolide resistance than the other villages (p=0.014). CONCLUSIONS: Annual mass treatment with oral azithromycin may alter the prevalence of drug resistant S pneumoniae in a community. Surprisingly, topical tetracycline may also increase nasopharyngeal pneumococcal resistance. Topical antibiotics may have an effect on extraocular bacterial resistance.
Assuntos
Antibacterianos/administração & dosagem , Azitromicina/administração & dosagem , Nasofaringe/microbiologia , Tetraciclina/administração & dosagem , Tracoma/tratamento farmacológico , Administração Oral , Administração Tópica , Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Criança , Pré-Escolar , Esquema de Medicação , Farmacorresistência Bacteriana , Feminino , Humanos , Lactente , Masculino , Doenças Nasofaríngeas/microbiologia , Nepal , Pomadas , Streptococcus pneumoniae/efeitos dos fármacos , Tetraciclina/uso terapêutico , Resistência a Tetraciclina , Fatores de TempoRESUMO
Mass administration of azithromycin to eliminate blindness due to trachoma has raised concerns regarding the emergence of antimicrobial resistance. During 2000, we compared the antimicrobial resistance of nasopharyngeal pneumococcal isolates recovered from and the prevalence of impetigo, respiratory symptoms, and diarrhea among 458 children in Nepal before and after mass administration of azithromycin. No azithromycin-resistant pneumococci were isolated except from 4.3% of children who had received azithromycin during 2 previous mass treatments (P<.001). There were decreases in the prevalence of impetigo (from 14% to 6% of subjects; adjusted odds ratio [OR], 0.41; 95% confidence interval [CI], 0.21-0.80) and diarrhea (from 32% to 11%; adjusted OR, 0.26; 95% CI, 0.14-0.43) 10 days after azithromycin treatment. The absence of macrolide-resistant isolates after 1 mass treatment with azithromycin is encouraging, although the recovery of azithromycin-resistant isolates after 2 mass treatments suggests the need for resistance monitoring when multiple rounds of antimicrobial treatment are given.
Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Cegueira/prevenção & controle , Tracoma/tratamento farmacológico , Antibacterianos/efeitos adversos , Azitromicina/efeitos adversos , Cegueira/etiologia , Criança , Pré-Escolar , Chlamydia trachomatis/efeitos dos fármacos , Farmacorresistência Bacteriana , Feminino , Gastroenteropatias/etiologia , Humanos , Lactente , Masculino , Nepal/epidemiologia , Infecções Respiratórias/etiologia , Streptococcus pneumoniae/efeitos dos fármacos , Tracoma/complicações , Tracoma/epidemiologiaRESUMO
We investigated the role of cholesteryl ester transfer protein (CETP) in hamsters by using a monoclonal antibody (MAb) that inhibited hamster CETP activity. MAbs were prepared against partially purified human CETP and screened for inhibiton of 3H-cholesteryl oleate (CE) transfer from LDL to HDL in the presence of human plasma bottom fraction (d > 1.21 g/ml). Antibody 1C4 inhibited CE transfer activity in both human plasma bottom fraction (IC50 = approximately 4 micrograms/ml) and in whole plasma from male Golden Syrian hamsters (IC50 = approximately 30 micrograms/ml). Purified MAb 1C4 was injected into chow- and cholesterol-fed hamsters, and blood was collected for analysis of plasma CETP activity and HDL lipid composition. Plasma CETP activity was inhibited by 70%-80% at all and HDL lipid composition. Plasma CETP activity was inhibited by 70%-80% at all times up to 24 h following injection of 500 micrograms MAb 1C4 (approximately 3.7 mg/kg). The amount of antibody required for 50% inhibition at 24 h post-injection was 200 micrograms (approximately 1.5 mg/kg). Inhibition of hamster CETP activity in vivo increased hamster HDL cholesterol by 33% (P < 0.0001), increased HDL-CE by 31% (P < 0.0001) and decreased HDL-triglyceride by 42% (P < 0.0001) (n = 36) as determined following isolation of HDL by ultracentrifugation. An increase in HDL cholesterol and a redistribution of cholesterol to a larger HDL particle were also observed following fast protein liquid chromatography (FPLC) gel filtration of plasma lipoproteins.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Proteínas de Transporte/fisiologia , HDL-Colesterol/sangue , Glicoproteínas , Esterol Esterase/fisiologia , Animais , Anticorpos Monoclonais , Arteriosclerose/sangue , Proteínas de Transferência de Ésteres de Colesterol , HDL-Colesterol/química , LDL-Colesterol/sangue , LDL-Colesterol/química , VLDL-Colesterol/sangue , VLDL-Colesterol/química , Cricetinae , Masculino , Mesocricetus , Tamanho da PartículaRESUMO
Our studies of anti-DNA antibodies in systemic lupus erythematosus have demonstrated a preferential use of the V kappa I family to encode light chains of antibodies that express the anti-DNA associated 3I idiotype. This idiotype is present on a high percentage of anti-DNA antibodies in approximately 80% of SLE patients1,2. In this study, we employed PCR to obtain V kappa I germline genes from a lupus patient in order to address the following questions: Do the V kappa I germline genes of an individual with autoimmune disease differ from those of healthy individuals? What V kappa I genes are used to encode autoantibodies and are they used to encode protective antibodies also? Does the V kappa I gene family display peculiarities in V gene segment rearrangement or somatic mutation? Our analysis shows that the coding region sequences of germline genes of an autoimmune individual are highly homologous to those of non-autoimmune individuals. In addition, the same germline genes can be utilized to encode antibodies to both exogenous and self antigens. While rearranged V kappa genes are ordinarily derived from the J kappa proximal region of the V kappa locus, V kappa I genes encoding autoantibodies derive primarily from the J kappa distal region. It is not yet clear if this applies equally to V kappa I encoded antibodies directed to foreign antigen.
Assuntos
Autoanticorpos/genética , Genes de Imunoglobulinas , Região Variável de Imunoglobulina/genética , Cadeias kappa de Imunoglobulina/genética , Lúpus Eritematoso Sistêmico/genética , Sequência de Bases , Humanos , Lúpus Eritematoso Sistêmico/imunologia , Dados de Sequência MolecularRESUMO
Our previous studies of anti-DNA antibodies in SLE have demonstrated a preferential use of V kappa I and V lambda II gene families to encode light chains of antibodies that express the anti-DNA-associated 3I and 8.12 idiotypes, respectively. In this study, we employed PCR to obtain V kappa I and V lambda II germline genes from lupus patients in order to compare the germline genes to genes encoding expressed V kappa I and V lambda II light chains and to analyze the extent of somatic mutation among autoantibodies that derive from these light chain families. Our analysis shows that the germline repertoire among all persons (autoimmune and healthy) is comparable and that somatic mutation is used to diversify autoantibodies as well as anti-microbial antibodies. We have observed that autoantibodies encoded by V kappa I and V lambda II genes have a higher number of amino acid replacements in CDRs than autoantibodies encoded by other VL gene families. In addition, there may be subtle differences in V gene usage that distinguish the V kappa I-encoded light chains from other expressed V kappa light chains.
Assuntos
Anticorpos Antinucleares/genética , Doenças Autoimunes/imunologia , Linfócitos B/imunologia , Rearranjo Gênico de Cadeia Leve de Linfócito B , Genes de Imunoglobulinas , Região Variável de Imunoglobulina/genética , Cadeias kappa de Imunoglobulina/genética , Cadeias lambda de Imunoglobulina/genética , Lúpus Eritematoso Sistêmico/imunologia , Mutação Puntual , Doenças Autoimunes/genética , Sequência de Bases , Biblioteca Gênica , Humanos , Idiótipos de Imunoglobulinas/genética , Idiótipos de Imunoglobulinas/imunologia , Lúpus Eritematoso Sistêmico/genética , Dados de Sequência Molecular , Reação em Cadeia da PolimeraseRESUMO
PURPOSE: To describe presumed activation of herpetic keratouveitis after argon laser peripheral iridotomy. METHOD: Case report. RESULTS: A 68-year-old man developed chronic, unilateral, anterior uveitis associated with decreased corneal sensation, focal keratitis, and increased intraocular pressure after argon laser peripheral iridotomy. Treatment with oral acyclovir and discontinuation of topical latanoprost resulted in prompt and continued control of both the intraocular inflammation and pressure. CONCLUSION: Herpetic keratouveitis may occur after argon laser iridotomy, and it should be considered when postoperative inflammation persists despite appropriate use of topical corticosteroids, particularly in patients with a history of herpetic eye disease.
Assuntos
Herpesvirus Humano 1/crescimento & desenvolvimento , Iris/cirurgia , Ceratite Herpética/etiologia , Terapia a Laser/efeitos adversos , Uveíte Anterior/etiologia , Ativação Viral , Aciclovir/uso terapêutico , Idoso , Antivirais/uso terapêutico , Doença Crônica , Glaucoma/tratamento farmacológico , Glaucoma/cirurgia , Humanos , Pressão Intraocular , Ceratite Herpética/diagnóstico , Ceratite Herpética/tratamento farmacológico , Latanoprosta , Masculino , Prostaglandinas F Sintéticas/uso terapêutico , Uveíte Anterior/diagnóstico , Uveíte Anterior/tratamento farmacológicoRESUMO
AIMS: To determine if macrolide resistant Streptococcus pneumoniae will be a major concern in areas that receive annual mass azithromycin distributions for trachoma. METHODS: A cross sectional survey was conducted of nasopharyngeal S pneumoniae isolates for susceptibility to azithromycin 1 year after administering a single dose of azithromycin to treat trachoma in a village in Nepal. RESULTS: S pneumoniae was isolated from 50 (86%) of 57 nasopharyngeal cultures and no resistance to azithromycin was detected. CONCLUSION: The authors were unable to demonstrate that mass azithromycin therapy for trachoma produced macrolide resistant S pneumoniae that persists until the next scheduled annual treatment.
Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Streptococcus pneumoniae/efeitos dos fármacos , Tracoma/tratamento farmacológico , Criança , Pré-Escolar , Estudos Transversais , Farmacorresistência Bacteriana , Feminino , Humanos , Lactente , Masculino , Nepal/epidemiologia , Prevalência , Saúde da População Rural , Infecções Estreptocócicas/epidemiologia , Tracoma/epidemiologiaRESUMO
AIM: Face seeking flies have long been thought to transmit Chlamydia trachomatis, the causative agent of trachoma, but this has never been proven. The four criteria proposed by Barnett, previously used to incriminate other arthropods suspected of transmitting disease, were examined. One of these criteria remains unmet: the repeated demonstration of the presence of C trachomatis on flies. The authors used polymerase chain reaction (PCR) to look for the presence of C trachomatis DNA on flies in the Gurage Zone of Ethiopia. METHODS: Using sticky paper, one fly was collected from the face of each of 103 children aged 1-10 years. The piece of fly paper to which the fly was attached was cut out, followed by the collection of an empty piece from an arbitrary area of the fly paper, which served as control. Roche Amplicor PCR kits were used to detect C trachomatis DNA. RESULTS: Evidence of C trachomatis by PCR was found on 15 of 103 flies versus 0 of 103 controls (p = 0.0001). CONCLUSION: These results meet the final criterion needed to incriminate flies as a vector of trachoma. However, interventional studies will be needed to show the importance of fly control.
Assuntos
Chlamydia trachomatis/genética , DNA Bacteriano/análise , Dípteros/microbiologia , Tracoma/transmissão , Animais , Vetores de Doenças , Humanos , Reação em Cadeia da Polimerase/métodosRESUMO
Herpetic eye disease is common and is frequently associated with intraocular inflammation or uveitis. Despite recent advances in measuring anti-herpes virus antibodies and viral DNA in ocular fluids, diagnosis remains largely clinical. The two more common syndromes include anterior uveitis, often associated with keratitis, and the acute retinal necrosis (ARN) syndrome. Treatment is complex and requires careful monitoring to provide the appropriate balance of antiviral medication and corticosteroids. Long-term prophylaxis with oral antiviral agents may be required in selected patients to help prevent the vision-compromising complications associated with recurrences.
Assuntos
Antivirais/uso terapêutico , Infecções Oculares Virais , Glucocorticoides/uso terapêutico , Infecções por Herpesviridae , Uveíte , Técnicas de Diagnóstico Oftalmológico , Infecções Oculares Virais/diagnóstico , Infecções Oculares Virais/tratamento farmacológico , Infecções Oculares Virais/virologia , Infecções por Herpesviridae/diagnóstico , Infecções por Herpesviridae/tratamento farmacológico , Infecções por Herpesviridae/virologia , Humanos , Uveíte/diagnóstico , Uveíte/tratamento farmacológico , Uveíte/virologiaRESUMO
There are many more dilemmas. You will have your own list but whatever is on it, the best approach usually boils down to one basic tenet ... 'To your own self be true!'
Assuntos
Ética Médica , Medicina de Família e Comunidade/normas , Confidencialidade , HumanosRESUMO
AIMS: The purpose of this study was to estimate the duration of treatment necessary for sequential acanthamoeba laboratory tests from corneal scrapings to become negative, and to assess predictors that affect this duration period. METHODS: We included all patients with at least one positive acanthamoeba culture or Giemsa stain at the F.I. Proctor Foundation Microbiology Laboratory from 1996 to 2009. A parametric survival analysis was performed among patients with repeat cultures to assess significant predictors for extended clearance time. Simulations were performed to estimate clearance time in the entire patient population, assuming imperfect sensitivity. RESULTS: Thirty-seven patients with laboratory evidence of acanthamoeba had testing at 69 time points. The median clearance time among eyes with repeat cultures was 42.5 days (interquartile range (IQR) 22.0-82.0 days; unadjusted parametric model). Initial visual acuity was the only predictor significantly associated with clearance time in univariate analyses (P<0.0001). Using initial visual acuity as a predictor for clearance time among the entire patient population, the estimated clearance time decreased to 38.7 days (95% confidence interval (CI) 27.9-53.5 days). When the imperfect sensitivity of the culture technique was also taken into account, the estimated clearance time was 44.1 days (95% CI 31.9-61.0 days). CONCLUSION: The duration of infection with acanthamoeba keratitis undergoing treatment has not been well characterized. In this report we estimate a median clearance time of approximately 6 weeks, with an IQR of 22-82 days.